The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study
Abstract
BACKGROUND: It remains uncertain if the excess cardiovascular risk of rofecoxib and celecoxib reported in clinical trials is present in routine practice and whether the use of other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) also carries an increased cardiovascular risk. We performed a population-based case-control study to examine the risk of myocardial infarction (MI) among users of various categories of nonaspirin NSAIDs. METHODS: Using data from hospital discharge registries in the counties of North Jutland, Viborg, and Aarhus, Denmark, and the Danish Civil Registration System, we identified 10,280 cases of first-time hospitalization for MI and 102,797 sex- and age-matched non-MI population controls. All prescriptions for nonaspirin NSAIDs filled before the date of admission for MI were identified using population-based prescription databases. Relative risk estimates for MI were adjusted for a history of cardiovascular disease, hypertension, diabetes mellitus, chronic bronchitis or emphysema, alcoholism, liver cirrhosis, upper gastrointestinal bleeding, rheumatoid arthritis, systemic lupus erythematosus and the use of high-dose aspirin, platelet inhibitors, insulin or oral hypoglycemic drugs, antihypertensive drugs, lipid-lowering drugs, oral anticoagulants, nitrates, penicillamine, gold, oral glucocorticoids, and hormone therapy before the date of admission for MI. RESULTS: Current users of rofecoxib had an elevated risk estimate for hospitalization for MI compared with nonusers of any category of nonaspirin NSAIDs (adjusted relative risk [ARR], 1.80; 95% confidence interval [CI], 1.47-2.21). Increased risk estimates were also found among current users of celecoxib (ARR, 1.25; 95% CI, 0.97-1.62), other cyclooxygenase-2 selective inhibitors (ARR, 1.45; 95% CI, 1.09-1.93), naproxen (ARR, 1.50; 95% CI, 0.99-2.29), and other conventional nonaspirin NSAIDs (ARR, 1.68; 95% CI, 1.52-1.85). The highest ARRs were found among new users of all examined drug categories. CONCLUSIONS: Current and new users of all classes of nonaspirin NSAIDs had elevated relative risk estimates for MI. Although the increased risk estimates may partly reflect unmeasured bias, they indicate the need for further examination of the cardiovascular safety of all nonaspirin NSAIDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Selection of Controls in Case-Control Studies
Wacholder, S., McLaughlin, J. K., Silverman, D. T., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116396 · Cited by 998
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Madsen, M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00591-7 · Cited by 460
Mamdani, M., Juurlink, D. N., Lee, D. S., Rochon, P. A., Kopp, A., Naglie, G., Austin, P. C., Laupacis, A., & Stukel, T. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16299-5 · Cited by 435
Aspirin use and chronic diseases: a cohort study of the elderly.
Paganini-Hill, A., Chao, A., Ross, R. K., & Henderson, B. E. (1989) · BMJ · doi:10.1136/bmj.299.6710.1247 · Cited by 396
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., & Gertz, B. J. (2001) · Circulation · doi:10.1161/hc4401.100078 · Cited by 352
Ray, W. A., Stein, C. M., Hall, K., Daugherty, J. R., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07370-1 · Cited by 326
Whelton, A., White, W. B., Bello, A. E., Puma, J. A., & Fort, J. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02661-9 · Cited by 310
Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.481 · Cited by 281
Watson, D. J., Rhodes, T., Cai, B., & Guess, H. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1105 · Cited by 238
Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction
Solomon, D. H., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1099 · Cited by 234
White, W. B., Faich, G., Whelton, A., Maurath, C., Ridge, N. J., Verburg, K. M., Geis, G. S., & Lefkowith, J. B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02265-2 · Cited by 230
Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
Kimmel, S. E., Berlin, J. A., Reilly, M., Jaskowiak, J., Kishel, L., Chittams, J., & Strom, B. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-3-200502010-00005 · Cited by 222
Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
Rahme, E., Pilote, L., & LeLorier, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1111 · Cited by 203
Confounding by Indication in Epidemiologic Studies of Commonly Used Analgesics
Signorello, L. B., McLaughlin, J. K., Lipworth, L., Friis, S., S??rensen, H. T., & Blot, W. J. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200205000-00005 · Cited by 178
Relationship Between COX-2 Specific Inhibitors and Hypertension
Solomon, D. H., Schneeweiß, S., Levin, R., & Avorn, J. (2004) · Hypertension · doi:10.1161/01.hyp.0000136134.31846.83 · Cited by 151
Reicin, A. S., Shapiro, D., SPERLING, R. S., Barr, E., & Yu, Q. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02201-9 · Cited by 136
Upper gastrointestinal bleeding among users of NSAIDs: a population‐based cohort study in Denmark
Mellemkjær, L., Blot, W. J., Sørensen, H. T., Thomassen, L., McLaughlin, J. K., Nielsen, G. L., & Olsen, J. H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01220.x · Cited by 135
Blind Assignment of Exposure Does Not Always Prevent Differential Misclassification
Wacholder, S., Dosemeci, M., & Lubin, J. H. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116105 · Cited by 77
Use of nonsteroidal anti‐inflammatory drugs and the risk of first‐time acute myocardial infarction
Schlienger, R. G., Jick, H., & Meier, C. R. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01637.x · Cited by 75
Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects
Shaya, F. T. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.181 · Cited by 67
COX‐2 selective non‐steroidal anti‐inflammatory drugs and cardiovascular disease
Ray, W. A., MacDonald, T. M., Solomon, D. H., Graham, D. J., & Avorn, J. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.798 · Cited by 24
Cited by
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee
Lane, N. E., Schnitzer, T. J., Birbara, C. A., Mokhtarani, M., Shelton, D. L., Smith, M. D., & Brown, M. T. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0901510 · Cited by 674
Using Recovery Modalities between Training Sessions in Elite Athletes: Does it Help?
Barnett, A. (2006) · Sports Medicine · doi:10.2165/00007256-200636090-00005 · Cited by 593
An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
Ong, C. K. S., Lirk, P., Tan, C. H., & Seymour, R. A. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.698 · Cited by 587
Metadata
- Authors
- Johnsen, S. P.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2005-05-09
- Volume
- 165
- Issue
- 9
- Pages
- 978
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2067621583
- Cited by
- 288
- References
- 32
- FWCI
- 27.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.